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ABSTRACT 
 
 
  
 The purpose of this project is to gain an understanding about the controversial topic of 
stem cells as an example of the impact of technology on society.  The first chapter describes the 
types and classifications of stem cells, and chapter-2 focuses on their benefits to society.  
Chapter-3 goes beyond the technology to discuss ethical concerns surrounding the use of stem 
cells, while chapter 4 describes their legal issues.  The authors provide their own conclusions 
based on the project research. 
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PROJECT OBJECTIVES 
 
 
 This IQP explored and examined the controversial topic of stem cells and their impact on 
society.   The purpose of chapter-1 is to convince the reader that stem cells are not all alike, so it 
describes a variety of different types of stem cells, how they are classified, their potencies, and 
their sources.  Chapter-2 discusses a variety of experiments and treatments performed with stem 
cells, as examples of their benefits to society.  In Chapter-3, the ethical concerns of using various 
types of stem cells were investigated.  Chapter-4 examines the laws enacted by the United States 
and internationally to govern stem cell usage.  Lastly, based on their research, the authors 
provide their own conclusions on the use of stem cells and their laws. 
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CHAPTER-1:  STEM CELL TYPES 
Alexander Sterling 
 
 Stem cells are a special type of cell that is relatively long lived and is capable of 
regenerating tissues.  Because of these properties, stem cells are the basis of the new field of 
regenerative medicine.  However, not all stem cells are alike.  Some types of stem cells destroy 
an embryo to obtain them, so are ethically controversial.  But not all types of stem cells destroy 
embryos.  The purpose of this chapter is to describe the various types of stem cells, as an 
introduction to later chapters on their uses, ethics, and legalities. 
 
Embryonic Stem Cells 
 Embryonic stem (ES) cells are probably the most well known type of stem cell.  Mouse 
ES cells were first isolated in 1981 by Gail Martin, who cultured early embryos in media 
containing growth factors from teratomas (Martin, 1981).  Human ES cells were first isolated 
and grown in the late 1990’s by two independent labs who designed in vitro co-culture systems 
for feeding the ES cells (Thompson et al., 1998; Shamblott et al., 1999).  ES cells are obtained 
from in vitro fertilized (IVF) embryos (Figure-1).  Newly fertilized eggs (diagram upper left) are 
grown about 5 days to the blastocyst stage (diagram upper right), where the cells have formed 
into a ball containing three structures, the trophoblast, blastocoel, and inner cell mass.  The 
trophoblast is the outer most layer of cells that surrounds the blastocoel which is a void in the 
mass of cells.  The inner cell mass is a group of cells located inside the ball that are segregated to 
one area, these are the ES cells.  When these cells are removed from the blastocyst, this usually 
destroys the embryo. 
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Figure-1:  Diagram of the Derivation of Embryonic Stem Cells.  The 
newly fertilized egg (upper left) is grown about 5 days to the blastocyst 
(upper right), in which ES cells reside.  The ES cells can be grown in 
vitro (usually as a co-culture) (diagram center), and can be 
differentiated into a variety of tissues (diagram lower).  
(Hyscience.com, 2010)  
 
 ES cells are pluripotent.  Potency refers to the ability of a stem cell to differentiate into 
other types of cells.  There are many different levels of potency in cells.  Newly fertilized 
embryos up to about the 8 cell stage are considered totipotent, and can produce all of the 
different types of cells in the body plus the extra embryonic tissues such as the placenta.  ES 
cells are pluripotent, and have the ability to become any cell in the body.  The next level of 
potency is known as mulitpotent.  This is when a cell can give rise to numerous, but restricted, 
lineages.  For example a hemocytoblast can differentiate into different types of blood cells, but 
cannot become a liver cell or a skin cell.  Unipotent cells can only become one kind of cell, 
usually the same type of cell representing the tissue the unipotent stem cell resides in.  
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 Tests can be performed to determine how potent a stem cell is. One test is to permit a 
portion of the stem cells to spontaneously differentiate (NIH.gov, 2006).   If the cells become a 
cell type that is also known to further differentiate, then the original cells have a high level of 
potency.  Researchers can also influence the stem cells to differentiate down a specific pathway.  
If the differentiated cells show characteristics of the three germ layers, they are considered ES 
cells.  A third test that can be preformed is to inject the stem cells into a mouse that has a 
suppressed immune system and see if a teratoma or benign tumor forms (NIH.gov, 2006).  ES 
cells are capable of forming teratomas. 
 ES cells are long lived and can be grown in vitro.  This growth allows the cells to be 
expanded, and represents an important property for their medical uses.  ES cell batches are 
usually grown for many months to allow researchers to examine the cells to see if they are 
growing correctly and normally.  ES cells produce key transcription factors which help them 
maintain their de-differentiated state during growth.  Nanog and Oct 4 are two key factors with 
this purpose, and these factors are also used to induce iPS cells (discussed below).  Grown ES 
cells can also have their chromosomes checked by microscopy for any obvious mutations or 
irregularities.   
 The major excitement around ES cells is their potential to cure diseases.  Since they have 
the distinctive ability to transform into any cell type in the body, they might be used to replace or 
repair almost any damaged areas of the body.  A primary example of this is the treatment of 
diabetes, a condition that occurs when islet cells in the pancreas stop making insulin.  Insulin 
normalizes the glucose and energy metabolism in the body.  As discussed in Chapter-2, ES cells 
have already been shown to be capable of differentiating into insulin producing cells, and have 
been used to treat mouse models of diabetes.    
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Induced Pluripotent Stem Cells 
 One of the most exciting discoveries in the past few years is the ability to form 
embryonic stem cell-like pluripotent cells from de-differentiated adult cells.  These cells are 
known as induced pluripotent (iPS) cells (Figure-2).  Human iPS cells were first discovered in 
2007 by Yamanaka’s group in Japan, who showed that pluripotent cells could be derived from 
facial skin fibroblast cells (diagram upper center) transfected with a combination of four 
transcription factors (blue in the diagram) (Oct4, Sox2, c-Myc, Klf-4) that help induce de-
differentiation (Takahashi et al., 2007).  The iPS cells are able to form ectoderm, mesoderm, and 
endodermal type cells (diagram lower).  Even though iPS cells appear to be able to differentiate 
into most cell types, at this time it is unclear whether they truly have the same potential as ES 
cells.  In mice, iPS cells have been used to create whole new mice, so these iPS appear to have 
true ES-like properties (Boland et al., 2009).  But other reports have shown that iPS cells grow 
slower and are less robust than ES cells (Dolgin, 2010). 
 
Figure-2:  The Formation of iPS Cells from Skin Fibroblasts.  Adult 
facial skin fibroblast cells (upper diagram) are transfected with a 
combination of genes encoding transcription factors (diagram right, 
blue) that help induce a de-differentiated state (diagram center).  The 
iPS cells can be grown and differentiated to form the three main 
embryonic tissues (diagram lower).  (SigmaAldrich.com, 2010) 
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 Since the original 2007 discovery of human iPS cells, the procedure for inducing iPS 
cells has been modified to omit one of the original transcrtiption factors (c-myc), an oncogene 
that induced tumors when the iPS cells were implanted into mice (Kim et al., 2008).  And the 
original virus method for delivering the transcription factor genes has been replaced by directly 
delivering the transcription factor proteins themselves into the cells (Yu et al., 2009).  One of the 
biggest potential benefits of using iPS cells for therapy is that because they are derived from the 
donor, they are genetically identical to the recipient, so there is less chance for the new cells to 
be rejected by the body.   More testing will be required before human trials can begin. 
 
Parthenogenic Stem Cells 
 Parthenogenesis is a special process by which an egg is fertilized without the use of a 
sperm.  In nature, this process is used especially in insects to produce worker ants and bees.  But 
the process does not normally occur in mammals, so chemicals such as strontium chloride or 
elecrical stimuli are used to induce the process.  The process blocks the normal expulsion of a set 
of chromosomes from the egg to produce an embryo with a normal number of chromosomes, but 
no father (Figure-3).   In April of 2004, the first fatherless mouse was created in the Tokyo 
University of Agriculture (Kono et al., 2004).   It is doubtful that artificial human 
parthenogenesis will ever be used to reproduce entire human beings, but parthenogenesis could 
be used to create embryos that can live long enough to make blastocysts from which ES cells can 
be derived.   
 
 
 
 10 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-3:  The Formation of Mammalian Partnenotes.  Chemicals or 
electrical stimuli are used to prevent the expulsion of one set of 
chromosomes from an unfertilized egg (diagram center) producing an 
embryo with a normal number of chrosomes (lower diagram) but no 
father.   (Parthenogenesis, 2007) 
 
 
 Monkey parthenote embryos were first created in 2001 (Cibelli et al., 2001), and were 
used in 2007 to derive monkey ES cells (Kim et al., 2007).  However, in monkeys and mice the 
induction of parthenogenesis frequently results in irregular development.  The reason for this is 
that mammals have imprinted genetic regions in their chromosomes.  In the case of mammalian 
parthenogenesis, the embryo would have twice the amount of maternally imprinted genes and no 
paternally imprinted genes.  So mammalian parthenote embryos do not survive long enough to 
produce adult animals.  But they can survive long enough to produce a 5 day old blastocyst from 
which ES cells can be isolated.  If these parthenote ES cells prove to be pluripotent, they could 
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replace the use of fertilized embryos to derive ES cells.  On June 26, 2007, the International 
Stem Cell Corporation (ISCC), a stem cell research company based in California, stated that they 
created human stem cells via parthenogenesis (Liebertonline.com, 2007). This breakthrough may 
lead to a treatment for degenerative diseases, but because the ES cells would be identical to the 
woman providing the egg, only that patient could be treated.  The process cannot be duplicated 
with sperm. 
 
Adult Stem Cells 
 Adult stem cells (ASCs) are a broad category of stem cells that includes almost any type 
of stem cell not isolated from an embryo.  This category includes any type of stem cell isolated 
from an adult organism or from umbilical cord blood.  Similar to ES cells, they can replicate and 
differentiate into tissues.  But unlike ES cells, they are hard to isolate, hard to grow, and have 
less differentiation potential.  They are ethically more desirable because embryos are not 
destroyed to obtain them.  Some types of ASCs are multipotent, such as mesenchymal stem cells 
(MSCs) or hematopoietic stem cells (HScs), but most ASCs are unipotent (Figure-4).  Generally 
adult tissues create an intermediary cell type prior to producing the completely differentiated 
state.  These intermediary cell stages are known as precursor or progenitor cells.  The precursor 
cells in adult tissues are less differentiated than ES cells, but can divide and yield differentiated 
cells.  These types of cells are generally considered as “committed” to being differentiated down 
a specific cellular development pathway.     
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Figure-4:  Example of Three Types of Adult Stem Cells.  Adult stem 
cells represent a broad category of stem cells isolated from adult tissues 
or from umbilican cord blood.  Examples include brain, heart, and bone 
marrow stem cells (upper, middle, and lower diagram, respectively).  
(Tripod.com, 2010) 
 
Hematopoietic Stem Cells 
 The hematopoietic system creates blood in the body.  There are many cellular 
components in this system, including red blood cells, platelets, granulocytes, and macrophages.  
Each of these parts has a specific role in the maintenance and function of the immune system and 
blood.  The erythrocytes transport oxygen over the body, platelets stop bleeding, granulocytes 
and macrophages help fight off foreign organisms in the body.  Hematopoietic stem cells (HSCs) 
are the source of all these cells.  On average each of us produce around one hundred billion 
(100,000,000,000) new cells from the hematopoietic system daily.  HSCs have been used in bone 
marrow transplants for over 50 years now to treat specific blood disorders, especially leukemia, 
and represent the best characterized type of stem cell (BMT Success Stories, 2006). 
 
 13 
Neuronal Stem Cells 
 Neuronal stem cells (NSCs) are a rare type of progenitor cell found in brain tissue (for a 
review see Gage, 2000).  These cells are very difficult to isolate as the vast majority of brain 
cells are not progenitors, but the hope is to be able to use them to treat brain disorders like 
Parkinson’s or Alzheimer’s diseases.  These cells appear to be especially found in the 
subependymal cells surrounding the brain ventricles (Morshead et al., 1993).  Currently scientists 
at the Stem Cell Research Group at Washington University are working on identifying factors 
that regulate neuronal differentiation; the research group is experimenting with the introduction 
of growth factors that can alter the cell type. 
 
Mesenchymal Stem Cells 
Mesenchymal stem cells (MSCs) are progenitors for a variety of other cells, including but 
not limited to osteocytes, chrondrocytes, adipocytes, neurons, oligodendrocytes, astrocytes, and 
different types of skeletal and cardiac muscle (HemoGenix, 2009).  Scientists originally 
discovered this multi-potency by growing MSCs in a “hematopoietic inductive micro-
environment” to make the cells produce hematopoietic supporting cells or stromal cells.  But 
when the cells were allowed to grow there were non-hematopoietic derived fibroblasts, 
endothelial cells, reticulum cells, fat cells, and macrophages.  MSCs have very few 
distinguishing characteristics, but a few markers used together help define the MSC.  This group 
of markers eliminates other types of cells and what remain is the MSC. 
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Figure-5:  Mesenchymal Stem Cell Differentiation.  MSCs (diagram 
left) are capable of forming a variety of mature cells types (diagram 
right) depending on the medium used for growth.  (HemoGenix, 2009) 
 
Skin Stem Cells 
In order to maintain adult epidermal homeostasis, the body employs two types of adult 
progenitor cells (Cotsarelis et al., 1999; Clayton et al., 2007).  The first kind are self-replenishing 
stem cells that maintain the stem cell base.  The stem cells undergo many rounds of division 
before finally differentiating.  The second kind of progenitor cell is the progeny of the stem cells.  
These progeny cells differentiate into epithelial cells.  Epithelial stem cells are currently used to 
replenish skin cells for burn patients. 
 
Myths About Stem Cells 
 As is typical for any complex technology, misinformation is abundant.  One myth is that 
all stem cells destroy embryos to obtain them.   This is false because of ASCs and iPS cells.  
Another myth is ASCs are as potent as ES cells.  This is not true based on current research, but 
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perhaps ASCs can at least be used to treat specific types of diseases, even if they are not as 
medically potent as ES cells.  Another myth is that stem cells have never been used to save any 
human lives yet.  This is false, as bone marrow transplants (containing hematopoietic stem cells) 
have been used for over 50 years now to save thousands of lives from leukemia.     
 Another myth is that U.S. scientists are prohibited from doing ES cell research based on 
current laws.  This topic will be discussed in Chapter-4, but the answer is under the Bush 
administration no new ES cell lines could be derived with federal funding, but this policy 
changed in 2009 with the Obama administration. 
 
Chapter-1 Conclusion 
 Multiple types of stem cells exist, from embryonic stem cells derived from fertilized 
eggs, to iPS cells induced from skin fibroblasts, to parthenote ES cells derived from unfertilized 
eggs, to adult stem cells isolated from an adult body.  Stem cell research at this point indicates 
that ES cells are the most potent in treating animal models of disease, they are the easiest to 
isolate and the easiest to grow.  Future research may prove that iPS cells provide a less 
controversial source of ES cells, even if they are not quite at potent as ES cells derived from 
fertilized eggs. 
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CHAPTER-2:  STEM CELL APPLICATIONS 
Gregory Voyta 
 
 
 The tissue regenerative potential of stem cells provides new therapies for treating a 
variety of conditions caused by damage to the body.  Some of the major areas currently being 
researched include diabetes, spinal cord injuries, Parkinson’s disease, cancer, stroke, 
autoimmune disorders, and others.  The main problems now include the difficulty of isolating 
adult stem cells (ASCs), getting ASCs or embryonic stem cells (ESCs) to differentiate down a 
specific pathway, and preventing their migration to other parts of the body.  This chapter focuses 
on the wide variety of applications for stem cells in the medical field and how far the different 
treatments have advanced.  This detailed discussion of their benefits is required to more fully 
discuss the topic of stem cell ethics in Chapter-3. 
 
Diabetes and Stem Cells 
 Stem cells are currently being used to attempt to treat diabetes.  Diabetes is one of the 
most widespread diseases, affecting millions of people worldwide.  It is steadily becoming more 
common, especially within the obese population.  There are two types of diabetes; type I occurs 
when the body attacks beta cells that produce insulin, while type II occurs when the body 
becomes partially resistant to insulin to a point where the body’s beta cells cannot produce 
enough insulin for the body (NIH, 2006, Chapter-7).  Through the use of stem cells, scientists are 
attempting to create healthy β-cells that can be reintegrated into the body, and that secrete insulin 
in a glucose-regulatable manner.  In researching possible ways to treat diabetes, scientists have 
used embryonic stem (ES) cells and adult stem cells (ASCs) from the bone marrow to attempt to 
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create new endocrine cells that will secrete insulin.  Research has been done on mice showing 
that it is possible to create functional pancreatic endocrine beta-cells (the cells that produce 
insulin) using ES cells.  A number of studies have produced results that suggest the ES cells are 
being properly accepted by the body and create more endocrine cells to produce insulin (Soria et 
al; 2000; Beilhack et al., 2003).   
 Research into using bone marrow to make endocrine cells has had its drawbacks, there 
have been mixed reviews in the studies done, some methods suffering from the injected cells 
inability to fuse with the body (Ianus et al., 2003), while others showed limited success (Hess et 
al., 2003.  Another approach to fighting diabetes uses stem cells to attempt to prevent the initial 
autoimmune destruction of the beta cells (Beilhack et al., 2005).  They used NOD (non-obese 
diabetic) mice, injecting them with hematopoietic stem cells, and found that the stem cells could 
block the development of autoimmune diabetes. 
 So overall, ES cells and ASCs do have the ability to differentiate into insulin producing 
cells, but for now have limited capacity to fuse properly in the body, so the overall efficiency of 
the treatments need to be improved before clinical testing on human patients can begin. 
  
Heart Disease and Stem Cells 
 Cardiovascular diseases are responsible for the deaths of millions of Americans annually, 
but leading the fight against these diseases are stem cells.  The causes of death from 
cardiovascular disease are mainly heart failure due to heart damage from a variety of causes 
including a pulmonary infarction (a heart attack), hypertension, and congestive heart failure 
(NIH, 2006, Chapter-6).  All of these symptoms occur from the heart overexerting itself and 
eventually exceeding the rate at which it can pump blood to the body.  Stem cells are now being 
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used to replace cells damaged in heart suffering from a variety of debilitating conditions.  The 
ultimate goal of the procedure is for the stem cells to fuse with cells in the damaged heart and 
help the body restore some of its cardiovascular functions.  The process should give people with 
heart problems more energy to live a more fulfilling life.   
 The process has been attempted using adult stem cells in animals, and has found that 
when hematopoietic cells are injected into areas around a recently damaged heart, the cells are 
able to differentiate into cardiac muscle and vascular endothelium (Jackson et al., 2001), 
increasing the function of damaged heart.  Other research has shown success in rodent models 
for ischemia, using a variety of stem cells, from myoblasts (Leobon et al., 2003) to mesenchymal 
stem cells (Amado et al., 2005).  These successes in animal studies bring hope for potential aid 
for people suffering from any of a variety of cardiovascular diseases. 
 Although some studies show that the injected stem cells have the ability to differentiate 
into the correct cells to repair the heart, the cells seem to have a tendency to migrate to many 
other parts of the body.  When using mononuclear bone marrow cells (Lunde et al., 2006) or 
intracoronary progenitor cells (Schachinger et al., 2006), researchers found the cells had been 
distributed all over the body, and the major factor in the success of the treatment was whether the 
cells stayed in the heart.  Other studies suggest that after acute myocardial infarction, there is less 
of a chance for significant repair at the wound site (Lunde et al., 2006; Schachinger et al., 2006), 
likely due to scar tissue formation, but this may change if more cells can be delivered to the 
damaged area or if scar tissue can be minimized.  Other general results suggest that the timing of 
the therapy after ischemia is important, and the sooner patients receive cell injections after 
cardiovascular problems the better chance they have at increasing heart function.  The field of 
heart regeneration through stem cells has potential to bring relief to millions who suffer from 
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heart problems, but it will require fine tuning of methods of injection to see effective and 
consistent results. 
 
Neurological Disorders and Stem Cells  
 Stem cells are also being used to repair damage done to nerve cells in a person’s brain to 
treat degenerative diseases like Parkinson’s disease and Huntington’s disease.  Neurological 
disorders stem from the lack of ability for the neurons in a person’s nervous system to 
communicate, so stem cell research is looking to successfully integrate new neural stem cells that 
have been created from stem cell lines (NIH, 2006, Chapter-3).  The new cells would have the 
ability to fill in the neural gaps in the brain creating a functioning nervous system (Sanberg, 
2007).   
 For Parkinson’s disease, deriving neurons that produce dopamine from stem cells and 
integrating them into the brain might allow the person to regain body function.  The human brain 
has the potential to regenerate itself, so it is also possible to stimulate those areas of the brain to 
respond and repair the damage.  Tests show in mice that when the correct growth factor is 
injected into the brain the stem cells already inside the brain to begin proliferation, directed 
migration, and neurodifferentiation (Fallon et al., 2000), effectively allowing the mouse brain to 
do most of the healing with its own material as opposed to putting the material in the body and 
hoping it will attach to the correct place.  Results from mouse models of Parkinson’s disease 
indicate adult neural stem cell and growth factor treatments when properly injected can be 
effective tools to alleviate problems caused by neurological disorders and aid in the repair and 
regeneration of the damaged nervous system (Kim et al., 2002).   
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 With respect to human studies, some experiments injecting embryonic neuronal cells into 
PD patients have been somewhat successful.  Some factors like age and the severity of the 
condition decreased the effectiveness of the treatments, and there were some side effects like 
dyskinesia (loss of voluntary movement in the body).  But the side effects have been minimal in 
other studies that are able to inject the cells without causing direct brain damage (Dunnett et al., 
2001).  The results of patient treatments vary from experiment to experiment, and one protocol 
has not proven to be substantially better.  Patients neurological scores improve after receiving 
treatment, but most trials only showed a substantial marked improvement in younger patients 
(Dunnett et al., 2001; Freed et al., 2001).  But in future experiments, as cell treatments are 
eventually optimized, cell therapy should give people who suffer from neurological damage a 
chance to partially alleviate their symptoms. 
 
Stroke and Stem Cells 
 Stem cells have also been applied to help patients recover from stroke more quickly and 
more completely.  The therapies for stroke target recovery of neurons in the brain, helping them 
regenerate.  The regeneration allows better communication between nerves in the body, and 
recovering motor functions.  The stem cells are converted into endogenous precursor cells which 
help integrate into the brain and take the place of neurons that die during strokes (Arvidsson et 
al., 2002).  There have been multiple studies done on animals using embryonic stem cells 
(Lindvall and Zaal, 2004; Steinbury, 2008).   
 The animal results suggest that treatments might eventually apply to human patients, but 
there are some problems that need to be worked out first. The problems presented by stem cell 
treatments for stroke could easily leave the patients in worse condition than they started.  One of 
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the problems with using stem cells is there is a chance that they will form tumors.  During lab 
testing on animals, scientists identified some tumors in the brain after the injection of stem cells 
and that would be an unacceptable risk to a human patient (Steinbury, 2008).  Other studies need 
to be conducted to minimize tumor formation, and the efficiency of the treatments needs to be 
improved so that the types of cells the stem cells differentiate into can be better controlled 
(Lindvall and Zaal, 2004).  With enough research, the field of stem cell therapy for stroke should 
bring much needed relief. 
 
Spinal Cord Injuries and Stem Cells 
 The field of spinal cord repair gained significant ground when research revealed stem 
cells as a possible treatment.  When people suffer from spinal cord injury their body no longer is 
able to send and receive signals from the spinal column, which results in diminished locomotion.  
Depending on the severity and location of the damage, it can produce a variety of injuries that 
prevent people from having complete use of their muscles and nerves.  The idea behind stem cell 
treatments is to restore the body’s neural receptors and transmitters and allow patients to recover 
some of the locomotion lost (Davies, 2006).   
 Some success has been reported in patients suffering from mild spinal cord damage (Liu 
et al., 2000).  The study showed that ES could differentiate in transplant patients into 
oligodendrites that stimulated axonal growth along the spinal cord (Davies, 2006).  Other studies 
in rats have shown that a variety of methods and cell types show potential for restoring a wide 
range of spinal column injuries (Kerr et al., 2003; Harper et al., 2004).  The potential to restore 
some level of locomotion to the body continues to be one of the most exciting fields in stem cell 
applications. 
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Stem Cells and Cancer 
 Not all the abilities of stem cells are positive; research has been done to try to discover if 
stem cells are directly related to cancer.  Recent theories in oncogenesis state that stem cells 
growing uncontrollably may initiate tumors.  Early theories on cancer were that residual fetal 
tissues in an adult body metabolize and expand into tumors, but this theory was soon discredited 
due to the lack of fetal tissues in most adults (Kneller, 2007).  Now, the most widely accepted 
theory is that adult stem cells that already exist in the body are exposed to the right set of 
conditions that cause them to become cancerous (Kneller, 2007).  This would explain why cancer 
is able to form in almost every part of the body, and how it can reappear after chemotherapy or 
other treatments.  The stem cell origin of cancer idea has launched a large field of research to 
isolate cancer causing stem cells throughout the body.  Most cancer-causing stem cells have been 
isolated by looking at the types of stem cells found in cancerous tumors (Kneller, 2007).  
Looking at where the cancer originated and the types of stem cells present in the tumor, scientists 
have been able to identify stem cells present in a variety of tumors.  The ultimate goal of the 
research is to create a drug that will prevent each type of stem cell from mutating into a 
cancerous cell. 
 However, not everyone supports the new cancer theory.  The idea of cancerous stem cells 
has led to debates over the validity of the research, and the idea that not just one type of cell 
(stem or otherwise) leads to a tumor.   For example, in the field of breast cancer research, 
scientists have identified what appear to be progenitor cells interacting with stem cells in a breast 
tumor (Polyak, 2007).  Thus, both types of cells would have to be targeted to destroy the tumor, 
and multiple drugs might be needed to prevent the disease.   
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 Scientists are also looking into blocking the signaling pathways of cancer-causing cells, 
which would prevent initial tumor growth.    One study showed that when two kinases that 
interact with MAP kinase (Mnk1 and Mnk2) are inhibited, the rate at which tumors grow is 
severely impeded (Ueda, 2002).  So more research must be performed to identify which cells 
contain these critical kinases, and what long term effects will result from their blockage.  This 
new branch of stem cell research suggests that it might be possible to prevent the outbreak of 
cancer if the right signaling pathways are blocked.  Hopefully when the field is more heavily 
researched we can find a way to stop stem cells from becoming cancerous. 
 
Stem Cells and Organ Growth 
 One of the most intriguing fields in regenerative medicine is the growing of new organs 
with stem cells.  The science behind these advanced procedures is to place a scaffold made of 
proteins into the site that needs repair.  The scaffold acts as a blueprint for the repair, and attracts 
stem cells to the region differentiating them into the cells needed for the body to regain function.  
The field has shown that it is possible to create parts of hearts and livers from scaffolds 
(Subbaraman, 2010).  Other studies have shown that bone growth can be initiated in animals 
using similar procedures, and once regeneration is complete the animals have nearly identical 
joint function as animals of the same age (Weintraub, 2010).  These studies show the potential to 
grow new organs for transplant and heal broken bones by using stem cells naturally found in the 
body.  Other researchers are using stem cells to grow bladders that have been used in Phase II 
testing on patients that suffer from spina bifida (Flanagan, 2007).  The new organs are grown 
using the patient’s own tissue to grow a new bladder from a scaffold the new bladder.  The new 
approach prevents many of the side effects like organ rejections that complicate organ 
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procedures on a regular basis.  This field may have the potential to replace almost any damaged 
organ.
 
 But first many challenges must be overcome to grow a complete organ.  The growth of a 
human bladder was done because of the simplicity of the organ and the overall ease of surgical 
placement (Flanagan, 2007).  But most organs have not been grown in completion or at full 
scale, so the developing scaffolds that will cause a stem cells to differentiate in the correct types 
of cells to create a functional organ is the most critical step preventing more advanced organ 
growth.  But the field has made many recent strides, like creating heart muscles that were able to 
beat under electric stimulation (Subbaraman, 2010).  The applications of this science have the 
potential to dramatically change the organ donor program, and allow people to have new organs 
grown from their own cells, but the ability to develop new organs is still inhibited by the 
complexity of the scaffolds created so far. 
 
Chapter-2 Conclusion 
 In conclusion, stem cells have the potential for almost unlimited applications when it 
comes to dealing with disease.   Depending on the type of stem cell used, their regenerative 
abilities allow them to differentiate into any type of cell in the body.  Our challenge is to control 
their growth to prevent cancer, and to devise methods to ensure the correct differentiation 
pathway is taken.  Most fields of stem cell research still need years of testing before trials can 
reach human patients, and it will be years after that before the treatments become available to the 
general public.  And many still believe that the use of ES cells is unethical, so the challenge will 
be to determine whether any adult stem cell treatment can work for a particular disease in lieu of 
using ES cells (this topic will be discussed in the next chapter).  The sheer variety of diseases 
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that stem cells are able to combat illustrate that stem cells might be able to help almost any 
person at some point in their lives, whether they have broken bones or need a  new organ.  
For now, stem cells show a great deal of promise in a wide variety of applications, and show the 
potential to revolutionize the way many major diseases are treated. 
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Chapter-3:  Stem Cell Ethics 
Gregory Voyta 
 
 The previous chapter focused on the benefits to society of stem cells (their medical uses), 
but in this chapter we go beyond stem cell technology to ask whether we should work with these 
cells.  Stem cell ethics usually focuses on embryonic stem cells and the embryos destroyed to 
obtain them, but these cells represent only some of the types of stem cells in use today.  This 
chapter will discuss different sides of the ethics debate, which is critical for understanding the 
legal issues in Chapter 4.  
 As discussed in detail in Chapter-1, stem cells are not all alike, and each type has its own 
ethics.  As a brief reminder, there are four main types of stem cells: adult stem cells (ASCs), 
embryonic stem (ES) cells, embryonic germ (EG) cells, and induced pluripotent stem (iPS) cells.  
ASCs are isolated from an adult body (or sometimes from cord blood) and have the potential for 
limited differentiation.  ASCs are hard to isolate and grow, but no embryos are destroyed to 
obtain them.  ES cells are isolated from 5-day old embryos created by in vitro fertilization (IVF).  
The embryo is usually destroyed during the isolation procedure.  ES cells are pluripotent, so have 
the best medical uses, and are relatively easy to isolate and grow in large numbers.  ES cells can 
also be obtained in animals by cloning via somatic cell nuclear transfer (SCNT), also known as 
therapeutic cloning (Devolder, 2005).  EG cells are isolated from aborted fetuses, and also have 
pluripotent potential, but not quite to the degree of ES cells (Devolder et al., 2005).  iPS cells are 
adult cells (usually skin fibroblast cells) induced to de-differentiate into pluripotent cells using 
transcription factors.  iPS cells do not destroy embryos to obtain them, but it is not yet proven 
whether they are truly as potent as ES cells. 
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Early Human Embryo Development 
 A discussion of early human development will help provide a framework for embryo 
ethics.  Following fertilization at day-0, the zygote begins dividing.  The cells remain totipotent 
through about the 8-cell stage (48 hrs).   At day-5, the embryo has become a blastocyst and 
between 5-8 days implants into the uterine wall.  The embryo in its second month of 
development may mark the beginning of sentient human life, because as the embryo approaches 
its eighth week many of the features that make a human start emerging.  Brain cells 
exponentially increase, forming almost 100,000 cells per minute (ScienceClarified.com, 2010).  
The development of the brain cells coincides with the emergence of the pineal gland in the brain, 
which generally becomes active on the 49
th
 day of gestation (Johnston, 2009).  This time period 
of the second month coincides well with Jewish, Muslim, and old Christian beliefs about when a 
fetus becomes distinctly human, which is around 40 days (Johnston, 2009).  Besides the 
emergence of the pineal gland and advanced brain growth, the seventh and eighth week also 
eliminates the tail that was originally present in the fetus, finishes creating most major organs, 
and moves them to the proper locations in the body, creates fingers and toes that are no longer 
webbed, closes the eyes of the fetus by creating eyelids (which will not be reopened until around 
the twenty-sixth week), begins the initial growth of distinct sex organs, and starts fetal muscular 
movement (Hagan et al. 1997; ScienceClarified, 2010).  After the eighth week the fetus begins to 
grow rapidly in size, having just finished the initial growth of most major organs.   
  
Religious Views of Stem Cells 
 The ES cell debate focuses on the status of the 5-day old human embryo destroyed to 
obtain these cells.  Is it murder to destroy the embryo?  When does life begin: at conception, at 
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implantation, at birth?  Looking into different religious perspectives will help explain people’s 
opinions on stem cell research, especially since most people identify with a religion.  The 
world’s major religions have different views on when life begins.  Although most large religions 
are so complex they have multiple points of view, most religions have general trends and leaders 
to help interpret how the creators of each religion might view complex topics today.  These 
leadership views by no means represent all people of a certain religion, but should represent a 
majority. 
 To begin the discussion, all five of the major religions support research with adult stem 
cells.  These cells do not destroy an embryo during their isolation, so even conservative 
Catholics support using ASCs so long as the cells are used to try to save lives according to Pope 
Benedict XVI (Catholic Online, 2008).  No lives are threatened by the ASC extraction.  But the 
main problem with using adult stem cells is they are not as effective as their embryonic 
counterparts.  ASCs do not have the ability to differentiate into as many tissues as ES cells, and it 
is difficult to grow enough of them to actually use in therapies.  Although hematopoietic stem 
cells (HSCs) have been used for decades to save lives in bone marrow transplants, other strong 
applications are still being researched.  The use of mesenchymal stem cells (MSCs) looks 
especially promising, and perhaps these cells can eventually replace ES cells for some disease 
treatments. 
 
Christianity and Stem Cells 
For Christianity, with its various subtypes, the topic of when personhood begins is 
complex.  Catholics argue life begins at conception (so are strongly against ES cells), while other 
churches argue a fetus is considered human only after 40 days for males and 80 days for females 
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(ChristianBibleReference.org, 2000).  It was not until 1869 that the Catholic Pope decreed that 
abortion at any point led to excommunication (ChristianBibleReference.org, 2000).  That view 
still holds today for much of the Catholic church who believe life begins at conception.  But 
other Protestants concede to a 15 day period on newly fertilized eggs, agreeing that research on 
these young cells is acceptable (Cousins and Geisert, 2005).  Some Protestant churches hold the 
same belief as Catholics, while others feel that stem cell research is appropriate when there are 
no other ways to conduct the same research (Cousins and Geisert, 2005).  
 
Judaism 
 Judaism holds that for the first 40 days of gestation a fetus is considered “as if it were 
simply water”, not fully human, and after 40 days the fetus is considered “like the thigh of its 
mother” (Dorff, 2002).  So Judaism allows research on 5-day old IVF embryos.  However, this 
religion does not allow a mother to abort an embryo to use it for research.  Judaism holds that the 
mother does not have a right to abortion unless it is to save her own life, because it is not until 
birth that the child becomes as fully human and distinct from the mother (Hug, 2006).  In relation 
to stem cell research Jews generally believe that developing cultures of stem cells is okay 
because they are “simply water” and do not consider it human, in that state the IVF embryos 
would not have the ability to develop into a full-fledged person (Dorff, 2002).  So Judaism 
permits using aborted fetuses (when done to save the mother’s life), and frozen IVF embryos that 
are planned to be discarded (Dorff et al., 2002).  So Judaism permits nearly all types of stem cell 
research done today, but not reproductive cloning. 
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Islam and Stem Cells 
 Islam’s Qur’an does not specifically mention stem cells, but guidelines can be taken from 
their literature gives a general idea of their beliefs.  The Qur’an indicates that a person’s “life 
force” is given to them either 40 or 120 days after conception, and after that time period 
abortions are generally disallowed (Syed, 2001).  This belief allows the use of 5-day old 
embryos.  But most Islamic scientists feel that the only type of stem cell research that should be 
fully allowed is on IVF embryos, not aborted tissue (Siddiqi, 2001).  Some Islamic scientists feel 
that stem cell research needs to be more heavily looked at to see if it goes against the teachings 
of the Qur’an, but does so far it does not appear to disavow it (Siddiqi, 2001).  So this creates 
varying views on stem cell research within the Muslim community, as with Christianity, but 
most Muslims believe working on an embryo less than 40 days old is acceptable.   
 
Hinduism and Buddhism 
 Buddhism and Hinduism typically do not support work on ES cells (Hug, 2005).  Their 
general doctrine sees all life as sacred, and that people are reincarnated after death into a new 
body (Knowles, 2008).  So these ideals would not permit the use of embryos for ES cell research.  
But Buddhism and Hinduism do believe in seeking out knowledge, which could be gained 
through this research (Knowles, 2008).  With respect to when an embryo becomes alive, this 
ranges from the moment of conception to seven months into pregnancy, depending on the 
specific Hindu or Buddhist community (Cousins and Geisert, 2005).  But even though these 
religions tend to respect life, ES research is still conducted in Hindu and Buddhist countries.  So 
in practice, seeking knowledge to benefit the living tends to outweigh the possible consequences 
to human life.  But the research is only allowed if it is for the greater good of mankind; research 
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for monetary gain is unacceptable (Hug, 2006).  So, even though ES cell research tends to go 
against the Buddhism and Hinduism ideal of preserving life, the overall benefit of mankind is 
considered more important than that of a small number of 5-day old embryos. 
 
Ethics of Cloning and Genetic Manipulations 
 Strong debates over cloning and genetic manipulation are pitting the religious and 
scientific communities against each other.  Human reproductive cloning is considered an 
abomination among all of the mainstream religions and governments (Madzarevic, 1998).  In 
fact, human reproductive cloning is currently banned in all countries organized enough to have 
such policies; no country currently permits it.  Some ideas have been proposed to create humans 
resistant to certain diseases, but such experiments are all banned.   Some people argue making 
disease resistant humans might lead to new diseases that are harder to fight, but that same 
argument can be applied to current day antibiotic treatments.   
 With respect to human therapeutic cloning, although one Korean study claimed success 
(Hwang et al., 2005), this study was later withdrawn for data fabrication, so human therapeutic 
cloning has not yet been achieved.  In this process, the nucleus from a patient’s skin fibroblast 
cell would be isolated, and then it would be injected into an enucleated egg.  The IVF embryo 
would be grown 5 days, then ES cells isolated.  This process is also known as somatic cell 
nuclear transfer (SCNT).  The advantage of SCNT ES cells is they would be genetically identical 
to the patient, so would not be rejected.  The U.S. currently bans both reproductive and 
therapeutic SCNT. 
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Chapter-3 Conclusion 
 The ethics debate on stem cell research has a wide variety of opinions, ranging from a 
comlete ban on ES cells cells, to a complete allowance of ES and SCNT research.  Many 
individual’s opinions are shaped by their religious background, which helps formulate their 
opinions on when a fetus becomes a human being.  The embryo ethics discussion actually has 
been going on for decades, since excess embryos were discarded from IVF clinics.  Catholics, 
Hindus, and Buddhists generally do not support ES cell research, while Muslims, Jews, and some 
Christians support it.   
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CHAPTER-4:  STEM CELL LEGALITIES 
Alexander Sterling 
 
As with all great advances in science, there is a storm of controversy with stem cells.  As 
discussed in the previous chapter, there is an ethical/religious debate about the use of ES cells.  
And as is typical of any controversial technology, there are laws to regulate the use of stem cells.  
The purpose of this chapter is to describe some of the laws regulating stem cell use, both in the 
U.S. and internationally. 
The biggest debate with stem cell research is the act of collecting ES cells from fertilized 
embryos is considered by some to be murder.  So the stem cell policies enacted usually address 
the use and source of fertilized embryos for research purposes.  Over the years, the United States 
has had many rulings on this embryo issue, including both national and state rulings.  And each 
new president and Congress has passed new bills and laws regarding the subject. 
 
Early U.S. Embryo Policies 
 The National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research in 1974 placed a ban on all federally funded research using fetal tissue to 
prevent the mistreatment of human subjects.  In 1975, an Ethics Advisory Board was established 
to oversee research on any fetal tissue originating from abortions, but in 1981 then President 
Reagan ended the ethics board’s charter, allowing the original 1974 ban to continue (Stem Cell 
Tracker, 2009).  
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President’s Clinton’s Stem Cell Policies 
 
 
 
 
 
 
 
 
 
                                                     (Mokellyreport, 2009) 
 
In President Bill Clinton’s 2004 book he says that “Everyone knows life begins 
biologically at conception.  No one knows when biology turns into humanity.” (Clinton, 2004) 
This quote was in reference to his stance on abortion.  President Clinton had a pro-abortion 
position, stating Roe v. Wade was the correct verdict.  Abortions used to be one of the primary 
sources to obtain fetal tissues for research, such as those used to treat Parkinson’s disease in 
animal models, and later in humans.  But this practice of using aborted fetal tissues has waned 
over the years, and has been replaced by a debate over the use of 5 day old in vitro fertilized 
embryos.  In President Clinton’s book “My Life” he talks about his former chief of staff Erskine 
Bowles’ children, both of which have diabetes.  At the time diabetes was responsible for 25% of 
all Medicaid costs (Clinton, 2004).   President Clinton supported ES cell research and the 
American Diabetes Association’s diabetes self-care program. 
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 Because of Clinton’s pro stance on embryo research, in 1993, he issued an executive 
order to overturn the original 1974 ban on embryo research.  However, under fire from critics, in 
1995, the Dickey-Wicker Amendment was passed by congress which prohibited federal funding 
for embryo research (Stem Cell Tracker, 2009).   In 1998, with the isolation and growth of 
human ES cells generating so much excitement, it was decided by a Department of Health and 
Human Services (DHHS) advisory committee that the amendment did not apply to ES cells, 
making their use legal, but not with federal funding.  Importantly, the Clinton administration 
mandated the National Institute of Health (NIH) to publish its guidelines on ES cell research.  In 
2000 it recommended that ES cells not be derived with public funding, the cells must be derived 
from excess IVF embryos initially created for reproductive purposes, and the embryos must be 
obtained with donor consent. 
 
 
President Bush’s Stem Cell Policies 
 
 
 
 
 
 
 
 
 
                                                           (TopNews, 2010) 
 
 42 
From the outset of his pre-election campaign, through his entire 10 years as president, 
President Bush argued that destroying an embryo is murder.  In August of 2001, President Bush 
enacted legislation that banned the federal funding for embryo research and deriving ES cells.  
Embryos destroyed prior to 2001 could be used for research, since those embryos had already 
been killed, but federal money could not be used to derive any new ES cell lines.  Congressmen 
floated bills trying to lift the ban, but in July of 2006, President Bush vetoed his first bill which 
would have lifted the ban on funding for stem cell research (Babington, 2006).  The bill would 
have granted money collect taxes for research and use of ES cells.  During the press conference, 
President Bush was joined on stage by children that were produced through “adopted” embryos 
that were previously frozen, and which could have been used for research if his ban did not go 
through.  President Bush stated that the taxpayer’s money should not go to support research on 
excess embryos from fertility clinics, even if they hold the possibility of medical breakthroughs 
and are already scheduled for disposal.  
During a meeting with the Prime Minister of Denmark President Bush said “I made my 
position very clear on embryonic stem cells, I’m a strong supporter of adult stem cell research, of 
course.  But I made it very clear to Congress that the use of federal money, taxpayers’ money, to 
promote science which destroys life in order to save life is – I’m against that.  And therefore, if 
the bill does that, I will veto it.” (Baker, 2005) 
President Bush said that the vetoed bill “would support the taking of innocent human life 
in the hope of finding medical benefits for others.”  He went on to state that “It crosses a moral 
boundary that our decent society needs to respect”, and it also stated that each child was at one 
time an embryo, and that these children are not additional parts.   
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There were of course many who opposed the President’s decision to veto the bill.  
Senator Richard J. Durbin said “Those families who wake up every day to face another day with 
a deadly disease or a disability will not forget this decision by the president to stand in the way 
of sound science and medical research” (Babington, 2006).  President Bush also received 
criticism on his veto from fellow conservatives.  Senate Majority Leader Bill First said “I am 
pro-life, but I disagree with the president’s decision,”  and he also stated that “Given the 
potential of this research and the limitations of the existing lines eligible for federally funded 
research, I think additional lines should be made available” (Babington, 2006).  The lines of 
which he speaks are the ES cell lines that researchers currently use to perform research, however 
the ban limited the total number of ES lines to relatively few which hindered research. 
Celebrities like Nancy Reagan and Christopher Reeve voiced their opinions on the 
medical potential of embryonic stem cells, and how such cells could be used to treat diseases 
such as Alzheimer’s, Parkinson’s, diabetes, spinal cord injuries, and other conditions.  They also 
criticized the use of adult stem cells, saying that embryonic stem cells have the ability to 
reproduce themselves better and transform into any kind of human tissue (Babington, 2006). 
There are an estimated 400,000 frozen embryos stored in U.S. fertility clinics, with most 
of these expected to be discarded as the donor parents do not want another person to raise their 
biological offspring.  President Bush commended all those who “adopted” these frozen embryos.  
However, even with federal funding offered to those who adopt a frozen embryo, there are still 
relatively few parents who actually adopt.  In 2006, there were 128 adoptions out of the 400,000 
embryos available, with the rest destroyed.  
President Bush and his supporters argued that these frozen embryos are synonymous with 
humans, and that research on them would be no different than doing research on death row 
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inmates.  President Bush said “If this bill introduced by Senator Warren Hatch were to become 
law, American taxpayers would for the first time in our history be compelled to fund the 
deliberate destruction of human embryos.”  This analysis was rejected by others, saying that it 
would make killers out of every couple that creates an unused embryo.  Senator Tom Harkin 
asked “If that’s murder, how come the president allows that to continue?” (Babington, 2006)  He 
goes on to say “Where is the outrage?” Harkin then called the veto “a shameful display of 
cruelty, hypocrisy, and ignorance.” 
One alternative to using embryos to collect stem cells is to save the umbilical cord and 
blood from a birth.  The Bush White House showed support for this legislation.  White House 
deputy press secretary Trent Duffy said “We need to look at the specifics of the kind of bill that’s 
being discussed on cord blood, but we think that that has some real promise” (Baker, 2005). 
 
President Obama’s Stem Cell Policies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                        (Uploads, 2009) 
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 Eight and half years after President Bush put a 2001 ban on embryonic stem cell research, 
the new President Obama rebuked it.  On March 9, 2009 President Obama reversed the ban on 
stem cell research (Hayden, 2009; Wilson, 2009). With this removal of the ban, federal funds 
will now go towards the study and research of embryonic stem cells.  President Obama said “At 
this moment, the full promise of stem cell research remains unknown, and it should not be 
overstated, but scientists believe these tiny cells may have the potential to help us understand, 
and possibly cure, some of our most devastating diseases and conditions”  (Childs and Stark, 
2009).  With the band lifted there is expected to be a great increase in the number of embryonic 
stem cell lines in existence.  The number of lines is expected to range anywhere from 400 to 
1,000, instead of the 21 that existed before.   
Upon President Obama’s order, the National Institute of Health had 120 days to create 
ethical guidelines for embryonic stem cell research.  The National Institute of Health stated they 
would find ways to streamline the process of research, and evaluate how promptly grant money 
can be distributed.  Most grant requests can take up to nine months to process which can delay 
the funds to the researchers for up to a year, but the National Institute of Health will try to 
accelerate the grant process to get the money out faster.  Melody Barnes, Director of the 
President's Domestic Policy Council, said "Encompassed in [the executive order] will also be the 
requirements around guidelines that will be drafted by the NIH [National Institutes of Health] as 
they ... work with others around the country to make sure we're handling the issue responsibly" 
(Childs and Stark, 2009).  In July 2009, the NIH Guidelines were published (Federal Register, 
2009; Majumder and Cohen, 2009).  Although some critics argued with the requirement that 
embryos be obtained only from IVF clinics created for reproductive purposes, others viewed the 
guidelines as a reasonable compromise, and far better than the 2001 legislation. 
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President Obama also signed a memorandum that will “restore scientific integrity in 
government decision making” says Melody Barnes (Childs and Stark, 2009).  The memorandum 
that was signed covers all types of scientific research, things including but not limited to energy 
and climate change.   
The former first lady Nancy Reagan, wife of the late President Ronald Reagan who had a 
difficult fight with Alzheimer’s disease, has been a strong supporter for stem cell research, and 
stated that she is “very grateful” that President Obama lifted the ban (Childs and Stark, 2009).  
Nancy Reagan said “These new rules will now make it possible for scientists to move forward. 
Countless people, suffering from many different diseases, stand to benefit from the answers stem 
cell research can provide.  We owe it to ourselves and to our children to do everything in our 
power to find cures for these diseases – and soon.”  Other disease advocacy organizations hail 
this move as an affirmative towards the treatment of diseases such as Parkinson’s and Type-1 
diabetes. 
At the conference where President Obama removed the ban were Allen Goldberg and 
Laurie Strongin, parents of Henry Strongin Goldberg who had a rare genetic Fanconi anemia and 
died at age 7.  His parents had used early stem cell technologies to try to cure their son.  In a 
statement Strongin said "Henry had a rare illness. Not one of the few stem cell lines that 
President Bush specified in his 2001 stem cell decision provided for research into Fanconi 
anemia or other devastating illnesses" (Childs and Stark, 2009). 
Michael Castle, the co-author of the stem cell legislation that was brought before 
President Bush and vetoed twice said “This single action symbolizes a new day for scientific 
research and highlights the importance of a strong federal role in prompting potentially life-
saving science” (Childs and Stark, 2009). 
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However, some oppose the decision by President Obama to allow embryo research.  
Millions of people are in opposition to this choice said House Minority Leader John Boehner  
(Childs and Stark, 2009).  John Boehner’s released a statement saying “Advancements in science 
and research have moved faster than the debates among politicians in Washington D.C., and 
breakthroughs announced in recent years confirm that the full potential of stem cell research can 
be realized without the destruction of living human embryos.  The question is whether taxpayer 
dollars should be used to subsidize the destruction of precious human life.  Millions of 
Americans strongly oppose that, and rightfully so” (Childs and Stark, 2009). Also, David 
Prentice, the senior fellow for life sciences for the Washington D.C.-based Christian advocacy 
group Family Research Council, stated similar dissatisfaction, "There are adult stem cells that are 
helping to improve patients' health and saving lives, and these new iPS cells that are providing 
basic research tools to study disease.  It's really a waste of resources to be moving in that 
direction now.  It's a waste of funding, and it's a waste of lives, both in terms of the embryos and 
the patients waiting for these advances. ... I think it's clear that this is perhaps just fulfilling a 
campaign promise that was ill conceived" (Childs and Stark, 2009). 
The public opinion of stem cell research has become more popular over the years.  In a 
recent poll, 59 percent of the American population is in support on relaxing the restrictions on 
stem cell research, and 35 percent are still opposed to this (Childs and Stark, 2009).   
The removal of the federal money embryo research ban by President Obama has most 
scientists and researcher excited about what possibilities are in store for scientific break troughs 
in the future.  Martin Pera a professor and founding director of the Eli and Edythe Broad Center 
for Regenerative Medicine and Stem Cell Research at USC said “This [Obama] decision is a 
major step forward for stem cell research in the United States.  The move will enable NIH-
 48 
funded researchers to work on valuable new embryonic stem cell lines ... to determine which cell 
lines are best suited to treat particular diseases"  (Childs and Stark, 2009). 
 
 
Individual State Policies 
 
 While there are national rulings on the topic of embryo research, as discussed above, each 
state can enact its own regulations to fund stem cell research. States can approve their own bonds 
to fund stem cell institutes to do embryo research.  These bonds were especially important during 
the Bush administration’s ban on receiving federal money for embryo research.   
 California was one of the first states to do this with the enactment of a 2 billion dollar 
bond to fund the International Stem Cell Center (ISCC) in San Francisco.  This was followed in 
2007 by Massachusetts that approved a one billion dollar bond to fund embryo research in 
Massachusetts, and especially to fund the world’s largest stem cell depository at the University 
of Massachusetts medical School in Worcester (Estes, 2007; News in Brief, 2008).  Although 
this legislation initially hit a few snags, it was finally enacted in 2009. 
 The governor of Ohio, Bob Taft, vetoed a ban that would have restricted state funding for 
embryonic stem cell research.  That ban would have guaranteed that no money from “Taft’s $500 
million Third Frontier initiative” would go towards research into stem cells.  The ban Taft said 
was too restraining than what President Bush had already put into place.  Many pro-life 
organizations greatly supported the ban.  The legislature director of Ohio Right to Life, Mark 
Lally commented “We strongly support the … amendment prohibiting the use of state grant 
funds for research that involves the destruction of human embryos to obtain their stem cells”  
 49 
(Ertelt, 2005).  Other supporters of the ban have concerns that embryonic stem cell research will 
eventually lead to human cloning.   
  
 
International Stem Cell Policies 
 
 The first country to actually conduct human stem cell experiments was China (Barnes, 
2006).  As controversy and debate over human embryonic stem cells rages in the “western” 
world, China has had little to no political turmoil over this.  Dr. Hong Peng, the vice president of 
Innovase Consulting says “Chinese scientists have made significant progress in the development 
of stem cell research."  But although China may be advancing in several stem cell research areas, 
there are legality concerns that still face China.  Dr. Albert Wai-Kit Chan said "While the 
Chinese are making some progress in protecting intellectual property (IP), the enforcement of IP 
protection laws is still weak compared to that of Western countries" (Barnes, 2006).  This means 
that determining who actually owns the ideas is under some scrutiny.  There have been 
occasional incidents of plagiarism and data falsification.  China will lose its competitive edge if 
these issues are not rectified.  Other countries with fairly liberal policies on embryo use include 
England, Sweden, Finland, India, Japan, and Australia (Figure-1, countries in dark brown 
color). 
 On the other end of the spectrum from countries with liberal stem cell policies, Germany 
called for a ban on stem cells research.  German Research Minister Annette Schavan said “The 
European Union science program should not be used to give financial incentives to kill embryos”  
(Deutsche Welle, 2006).   Besides Germany, Austria, Poland, Slovakia, Lithuania Luxembourg, 
and Malta are also against embryo and ES cell research. 
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Figure-1:  Different Countries Policies on Stem Cells and Embryos.  
Superimposed on the world map in colors are countries with permissive 
stem cell policies (dark brown), moderate stem cell policies (light brown), 
or no stem cell policies (yellow).  [http://mbbnet.umn.edu/scmap.html] 
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PROJECT CONCLUSIONS 
 
 
 
 Based on the research performed for this project, the authors provide their own 
conclusions on a few key points for stem cells.  With respect to the controversial topic of 
embryonic stem (ES) cells, the authors believe it is appropriate to work with these cells and to 
derive new ES cell lines.  The authors believe the benefits of ES therapies to exisiting individuals 
with specific kinds of diseases outweighs the detriment to an IVF embryo only 5-days old.  And 
many of the IVF embryos are slated for discard anyway, so might as well be used to try to save 
lives.  As a nod to others holding that ES cell research is wrong, we believe that induced 
pluripotent stem (iPS) cells and adult stem cells (ASCs) should be used to treat a specific disease 
if those cells have been shown to work as well as ES cells for that disease, otherwise ES cells 
should be used.  Unfortunately, the effectiveness of ES cells is usually higher than iPS and ASCs 
for most areas of stem cell research.  Developing ASC treatments, even if not quite as effective 
as ES treatments, will also be important to treat patients who are against using ES cells.   
 With respect to the best source for the embryos to derive ES cells, the authors believe 
excess IVF embryos originally created for reproductive purposes should be used first, then if 
those become exhausted we believe embryos should be created for research purposes.  Having 
women donate eggs is an acceptable option to us, but without pay which we believe would 
provide an incentive to push underpriviledged women who need the money. 
 With respect to laws regulating stem cell use, the authors of this report support the 
current United States policies under President Obama, who in 2009 overturned the 2001 Bush 
ban on using federal money to developed ES cell lines for research.  These laws should help 
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develop treatments for a large variety of diseases, while still being sensitive to the source of 
embryos.  Although some types of adult stem cell treatments using hematopoietic stem cells have 
been around for decades, and have already saved thousands of lives in bone marrow transplants, 
hopefully future stem cell therapies will eventually be developed to treat a great variety of 
diseases.  
 
